HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that clinical trial data from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the New England Section of the American Urological Association Meeting in Boston this week on September 28. The paper is authored by leading clinical research investigators participating in the U.S. clinical trials of NX-1207.
